SCHEMBL6649136

SCHEMBL6649136

COC(=O)c1ccc(Cl)cc1N(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.60
NR4A2 P43354 2/20 0.49
POLB P06746 1/20 0.48
MCOLN3 Q8TDD5 1/20 0.48
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
MAPT P10636 3/20 0.44
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4362314 0.86 ABL1 (0.56) ABL1NR4A2SLC6A4SLC6A3RXFP1
SCHEMBL7643547 0.85 ABL1 (0.55) ABL1NR4A2POLBMCOLN3SLC6A4
SCHEMBL7556668 0.83 KMT2A (0.64) ABL1NR4A2POLBMCOLN3MAPT
SCHEMBL27388939 0.82 ABL1 (0.51) ABL1NR4A2POLBMCOLN3SLC6A4
SCHEMBL8922678 0.81 KDM4E (0.59) MAPTSMN1; SMN2KMT2AALDH1A1CA12
SCHEMBL7685417 0.81 POLB (0.50) ABL1NR4A2POLBMCOLN3RXFP1
SCHEMBL27432636 0.81 ABL1 (0.50) ABL1NR4A2POLBMCOLN3SLC6A4
SCHEMBL6643737 0.80 SMN1; SMN2 (0.57) MAPTRAB9ASMN1; SMN2KMT2AALDH1A1
SCHEMBL12861272 0.80 FSCN1 (0.49) ABL1MAPTSMN1; SMN2KMT2AALDH1A1
SCHEMBL6100118 0.80 ABL1 (0.70) ABL1NR4A2SLC6A4SLC6A3RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR ABL1 721/4885NR4A2 39/4885POLB 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.